Cisplatin-Induced Hearing Loss, Oxidative Stress, and Antioxidants as a Therapeutic Strategy—A State-of-the-Art Review
Cisplatin is an established component of treatment protocols for various solid malignancies but carries a significant potential for serious adverse effects. Ototoxicity from cisplatin treatment is an important dose-limiting toxicity that manifests as bilateral, progressive, irreversible, dose-depend...
Saved in:
| Main Authors: | Olaf Rose, Tim Croonenberg, Stephanie Clemens, Tobias Hinteregger, Stefanie Eppacher, Petra Huber-Cantonati, Marta Garcia-Miralles, Raffaella Liuni, Silvia Dossena |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Antioxidants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3921/13/12/1578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population
by: Mohammad Shahbazi, et al.
Published: (2025-08-01) -
Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy
by: Nesrine Benkafadar, et al.
Published: (2016-10-01) -
Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancer
by: Nienke Streefkerk, et al.
Published: (2025-06-01) -
Stress granules formation in HEI-OC1 auditory cells and in H4 human neuroglioma cells secondary to cisplatin exposure
by: Hebatallah Abdelrasol, et al.
Published: (2024-10-01) -
The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy
by: Charlotte W. Duinkerken, et al.
Published: (2024-08-01)